Oaktree Acquisition Corp. III Life Sciences financial statements
Income statement, balance sheet and cash flow statement for the last 1 fiscal years, taken from the XBRL data Oaktree Acquisition Corp. III Life Sciences files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2025
Operating income
-1.2
Interest income
8.48
Other non-operating income
8.48
Net income
7.29
Balance sheet
FY2025
Cash and equivalents
1.43
Other current assets
0.11
Total current assets
1.55
Total assets
203
Accounts payable
0.5
Total current liabilities
1.3
Total liabilities
8.32
Paid-in capital
0
Retained earnings
-6.77
Shareholders' equity
-6.77
Total equity
-6.77
Total liabilities and equity
203
Cash flow statement
FY2025
Net income
7.29
Cash from operations
-0.42
Cash from investing
0.5
Cash from financing
0
Net change in cash
0.08
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $10.78 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on assets (ROA)
3.3%
Net income / average total assets.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
0.73x
Current assets / current liabilities.
Quick ratio
0.68x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.68x
(Cash + short-term investments) / current liabilities.
Was Oaktree Acquisition Corp. III Life Sciences profitable in fiscal 2025?
Yes. Net income was $7.3M, a net margin of -.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.